USPTO Awards IntelGenx Patent Protecting Rizaport

The USPTO has granted IntelGenx a patent protecting Rizaport, an oral film of rizatriptan benzoate for the treatment of acute migraines.

In 2015, the Federal Institute for Drugs and Medical Devices of Germany granted Rizaport marketing authorization, according to the company.

The patent allowance is one step toward broadening the company’s patent portfolio that supports IntelGenx's proprietary VersaFilm technology, said Horst Zerbe, president and CEO of IntelGenx. — Anisa Jibrell